drugset / Trial / NCT03858478
Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FAST
Phase 4
Unknown
110 enrolled
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
NaSingle-groupOpen-labelTreatment
Summary
Evaluation of antiretroviral treatment adherence using determination of Bictegravir, Emtricitabine and Tenofovir with new HIV patients in France
Timeline
- Start
- 2019-11-18
- Primary completion
- 2021-03-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bictegravir | Small molecule | 50 mg | — |
| Subject | emtricitabine | Other / unclassified | 200 mg | — |
| Subject | tenofovir alafenamide | Small molecule | 25 mg | — |
Indications
No indication recorded.